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Association between Rare Variants in AP4E1,
a Component of Intracellular Trafficking,
and Persistent Stuttering
M. Hashim Raza,1,7 Rafael Mattera,2 Robert Morell,1 Eduardo Sainz,1 Rachel Rahn,1 Joanne Gutierrez,1
Emily Paris,1 Jessica Root,1 Beth Solomon,3 Carmen Brewer,1 M. Asim Raza Basra,4 Shaheen Khan,5
Sheikh Riazuddin,6 Allen Braun,1 Juan S. Bonifacino,2 and Dennis Drayna1,*
Stuttering is a common, highly heritable neurodevelopmental disorder characterized by deficits in the volitional control of speech.
Whole-exome sequencing identified two heterozygous AP4E1 coding variants, c.1549G>A (p.Val517Ile) and c.2401G>A (p.Glu801Lys),
that co-segregate with persistent developmental stuttering in a large Cameroonian family, and we observed the same two variants in
unrelated Cameroonians with persistent stuttering. We found 23 other rare variants, including predicted loss-of-function variants, in
AP4E1 in unrelated stuttering individuals in Cameroon, Pakistan, andNorth America. The rate of rare variants inAP4E1was significantly
higher in unrelated Pakistani and Cameroonian stuttering individuals than in population-matched control individuals, and coding var-
iants in this gene are exceptionally rare in the general sub-SaharanWest African, South Asian, and North American populations. Clinical
examination of the Cameroonian family members failed to identify any symptoms previously reported in rare individuals carrying ho-
mozygous loss-of-function mutations in this gene. AP4E1 encodes the ε subunit of the heterotetrameric (ε-b4-m4-s4) AP-4 complex,
involved in protein sorting at the trans-Golgi network.We found that the m4 subunit of AP-4 interacts with NAGPA, an enzyme involved
in the synthesis of the mannose 6-phosphate signal that targets acid hydrolases to the lysosome and the product of a gene previously
associated with stuttering. These findings implicate deficits in intracellular trafficking in persistent stuttering.Introduction
Stuttering is a common neurodevelopmental speech disor-
der characterized by repetitions, prolongations, and inter-
ruptions in the flow of speech.1 Although twin and adop-
tion studies have demonstrated high heritability of this
disorder,2–5 Mendelian segregation does not typically
occur,6 which has rendered mutation identification diffi-
cult. We have previously used consanguineous families to
identify associated loci,7–9 and at one of these loci on chro-
mosome 12, we have identified rare coding variants in
GNPTAB (MIM: 607840), as well as in the functionally
related genes GNPTG (MIM: 607838) and NAGPA (MIM:
607985), which are associated with stuttering in popula-
tions from North America, England, Brazil, Pakistan, and
Cameroon.10 Although rare coding variants in these genes
together might account for 8%–16% of cases of familial
persistent stuttering,11 a large fraction of the heritable
causes of stuttering remain unidentified.
We have previously reported a large polygamous kindred
from Cameroon, West Africa, in which many members are
affected by persistent developmental stuttering. A linkage
study indicated that multiple associated genes located on
chromosomes 2, 3, 14, and 15 are acting in different
branches of this family.12 We performed whole-exome
sequencing, which revealed that two rare coding variants
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The American(AP4E1 [MIM: 607244]) co-segregate with stuttering in
11 members of sub-pedigree E of this family, which had
previously demonstrated linkage to this region of chromo-
some 15. Additional sequencing in unrelated stuttering
individuals from three different continental populations
revealed additional rare variants in this gene and moti-
vated cell biological and clinical studies of the effects of
these variants.Material and Methods
Individuals with non-syndromic persistent developmental stutter-
ing were enrolled with written informed consent under NIH pro-
tocol 97-DC-0057, as previously described.10,12 Documented
neurologically normal control DNA samples (NDPT; n ¼ 368)
were obtained from the National Institute of Neurological Disor-
ders and Stroke (NINDS) panels NDPT006, NDPT020, NDPT023,
NDPT079, NDPT082, and NDPT093 from the Coriell Cell Reposi-
tory. Unrelated affected individuals and population-matched
control individuals included Pakistani affected (PKST þ PKSTR;
n ¼ 132) and control (PKNR; n ¼ 96) individuals, Cameroonian
affected (STCR þ CAMST01; n ¼ 93) and control (RC; n ¼ 94) in-
dividuals, and North American affected individuals, including
those from our NIH group (NA þ NIH ¼ 711). Stuttering was diag-
nosed according to the Stuttering Severity Index 3 (SSI-3) and as
previously described.13,14 Individuals were classified as affected if
they displayed stuttering dysfluencies at a rate ofR4% of syllables
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self-report, and no genotypic evidence for relatedness among
these subjects was observed.
Whole-exome sequencing was performed with the Agilent Sure-
Select Human All Exon V4þUTRs (71 MB) exome capture kit and
subsequent analysis on the AB5500 SOLiD sequencer. Dideoxy
sequencing of exons and their 50-bp flanking regions was per-
formed with an AB 3730xl instrument, and sequence traces were
analyzed with DNASTAR SeqMan Pro version 9.1.0. The sequence
data of random individuals were obtained from the final phase of
the 1000 Genomes Project (3,068 individuals) and the NHLBI
Exome Sequencing Project (ESP) Exome Variant Server (~6,400 in-
dividuals) and by dideoxy sequencing of population-specific
matched control individuals (the 558 subjects described above).
The chromosomal phase of the c.1549G>A (p.Val517Ile) and
c.2401G>A (p.Glu801Lys) variants in AP4E1 was inferred from fa-
milial segregation andwasmeasured directly by cloning of RT-PCR
products covering exons 13–21 of AP4E1 mRNA from Cameroo-
nian unrelated individuals and by subsequent sequencing of
individual clones.
Clinical examinations were performed at the NIH Clinical Cen-
ter and included assessment of medical history, physical examina-
tion, neurological evaluation, audiological examination, X-rays of
lower limbs, and brain MRI and fMRI.
Construction of AP-4 ε subunit expression vectors involved the
pGADT7-human AP-4 ε subunit construct,15 which was subjected
to site-directed mutagenesis (QuickChange, Agilent) for removal
of the internal XhoI site. The human ε cDNA without the internal
XhoI site was subsequently amplified by PCR with primers
including KpnI and XhoI sites at the 50 and 30 ends, respectively.
The resulting PCR product was subsequently ligated into the
KpnI and XhoI sites of a modified pcDNA 3.1 vector containing
Strep and FLAG epitopes. This ligation generated pcDNA 3.1-
TSF-ε, a construct that is based on the pcDNA 3.1/Myc-His A
MCS (Invitrogen) backbone and directs the expression of human
ε tagged at its N terminus with TSF (two Strep and one FLAG) epi-
topes. The pcDNA 3.1-TSF-ε was subjected to site-directed muta-
genesis for the generation of the ε variants analyzed in this study.
All engineered variants were confirmed by sequencing in both
directions.
A cDNA encoding the cytosolic tail (residues 475–515) of the
human N-acetylglucosamine-1-phosphodiester alpha-N-acetyl-
glucosaminidase (NAGPA) was amplified by PCR from the
pCMV6-Entry-h NAGPA construct (Origene Technologies) with
primers containing EcoRI and XhoI sites. The PCR fragment was
subsequently subcloned into the corresponding sites of the
Gal4-binding domain (BD) yeast two-hybrid (Y2H) vector pGBKT7
(Clontech). The p.Tyr486Ala, p.Tyr488Ala, and p.Leu491Ala sub-
stitutions were introduced by site-directed mutagenesis of the
pGBKT7-NAGPA tail construct.
HEK293T cells were cultured in DMEM with high glucose sup-
plemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin on 100-mm dishes at 37C under
95:5 air:CO2. Cells were transfected with pcDNA 3.1-TSF-ε con-
structs at ~30%–50% confluency at a ratio of 7 mg of DNA per
100-mm dish with the X-tremeGENE9 reagent (Roche) and Opti-
MEM I Reduced Serum Medium (Life Technologies). Approxi-
mately 24 hr after transfection, cells were gently washed twice
with PBS at room temperature and lysed for 30 min at 4C in
800 ml of 50 mM Tris/HCl (pH 7.4), 75 mM NaCl, and 0.8% (v/v)
Triton X-100 supplemented with protease inhibitors (EDTA-free
Complete, Roche). Cell lysates were spun for 10 min at 21,000 3 g
and 4C, and the supernatants were kept at80C.716 The American Journal of Human Genetics 97, 715–725, NovembAP-4 complex assembly was assayed with thawed lysates of
HEK293T cells transfected with TSF-ε constructs that were centri-
fuged for 2 min at 16,000 3 g and 4C. The supernatants were
incubated overnight at 4C with 60 ml of StrepTactin Sepharose
beads (IBA) that had been previously washed twice by resuspen-
sion in PBS containing 0.01% (v:v) Triton X-100 and centrifuga-
tion at 4,0003 g. Beads with immobilized complexes were washed
three times by resuspension in 50 mM Tris/HCl (pH 7.4), 75 mM
NaCl, and 0.1% (v/v) Triton X-100 and microfuge centrifugation
(2 min at 4,000 3 g and 4C) and washed twice by resuspension
in PBS followed by centrifugation. Washed beads were eluted by
incubation with 50 ml of 13 d-desthiobiotin-containing elution
buffer (IBA) in PBS for 20 min at 25C and subsequently centri-
fuged for 2min at 16,0003 g and room temperature. Supernatants
with eluted proteins were subjected to SDS-PAGE and immuno-
blotting with rabbit antiserum against the C-terminal region of
the b4 subunit of AP-4 (anti-b4c)
16 and with mouse monoclonal
anti-FLAG M2 antibody (Sigma-Aldrich). Samples of the original
cell lysates were also subjected to SDS-PAGE and immunoblotted
with anti-FLAG antibody for analysis of the differences in the
expression levels of the different recombinant ε constructs. Immu-
noblots were developed with horseradish-coupled secondary anti-
bodies and Western Lightning Plus-ECL reagent (PerkinElmer).
Films were analyzed by densitometry with Image J software
(version 1.48v).
The constructs encoding the m subunits of the adaptor com-
plexes AP-1A, AP-1B, AP-2, AP-3A, AP-3B, and AP-4 subcloned
into the Gal4-activation domain Y2H vector pACT2 (Clontech)
have been described.17 Y2H assays were performed as previously
described18 with the AH109 reporter yeast strain. Positive and
negative controls for the assays are described in the Figure 3
legend.Results
Stuttering in Family CAMSTO1
Cameroonian family CAMST01 has been previously
described12 and contains a large fraction of individuals
who have persistent stuttering with an onset at age
2–5years. The familymembers evaluated in this study speak
multiple languages (English, French, and/or Lamnso) and
stutter in all of the languages they speak. They report that
their stuttering is exacerbated when they are under stress
oruse the telephoneand that some improvement influency
has occurred with age. No non-stuttering speech pathol-
ogies were observed in these family members during evalu-
ation at theNIHClinical Center.Overall, the speechhistory
and symptoms in all eight subjects are consistent with
typical persistent developmental stuttering.
Identification of Variants in AP4E1
Family CAMST01 displays significant evidence of genetic
linkage between persistent stuttering and multiple loci,
including a discontinuous region in 15q.12 Whole-exome
sequencing was performed on affected individuals II-111,
III-142, III-145, III-147, III-148, and IV-200 in sub-pedigree
1E, as shown in Figure 1B, and on affected individuals III-
125, IV-175, and IV-184 in sub-pedigree B, as shown in
Figure S3. These sub-pedigrees displayed linkage to twoer 5, 2015
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Figure 1. Identification of Rare Variations in AP4E1
(A) Bioinformatic-analysis pipeline applied to whole-exome sequence data from chromosomal region 15q.
(B) Co-segregation of the chromosome containing the c.1549G>A and c.2401G>A variations of AP4E1 in Cameroonian family
CAMST01, sub-pedigree E. Dideoxy sequencing traces of representative heterozygous c.1549G>A (p.Val517Ile) and c.2401G>A
(p.Glu801Lys) variations are shown.closely linked but non-overlapping loci in chromosomal
region 15q12 (Figure 1A). Within this region, three posi-
tional candidate genes (GANC [MIM: 104180], GATM
[MIM: 602360], and GALK2 [MIM: 137028]) were also
fully dideoxy sequenced. The whole-exome single-endedThe Americansequencing with 70 bp reads produced a mean coverage
depth of 25.63 (range 19.03–37.93). Analysis using Life-
scope identified a mean of 20,655 variants (range
19,604–21,708 variants) per exome. These variants were
subjected to bioinformatics filtering analysis, summarizedJournal of Human Genetics 97, 715–725, November 5, 2015 717
in Figure 1A. In the first step, variants outside the linkage
intervals in sub-pedigrees 1E and 1B were eliminated, leav-
ing a total of 3,632 variants, all residing within the previ-
ously demonstrated linkage regions and the short region
between them12 in 15q. Many of these variants occurred
commonly in the 1000 Genomes phase 3 dataset (which
contains 405 individuals with sub-Saharan West African
ancestry similar to that of Cameroonians) or in the NHLBI
ESP6400 dataset. These were eliminated from consider-
ation, and rare variants, defined as those with a frequency
of 0.01 or lower in 1000Genomes, were considered further.
Of the remaining 270 variants, we focused on the 66 non-
synonymous coding variants on the basis of the hypothe-
sis that the causative allele in sub-pedigree 1B and/or 1E of
CAMST01 is a coding allele of large effect. Nine of these 66
variants occur in more than one affected individual, and
six of these nine are predicted to cause non-synonymous
changes. Of these six, two occur frequently in our normal
Cameroonian control individuals, and two reside in the
area between the two linkage regions in 15q and are
considered off target. The remaining two are in AP4E1
(GenBank: NM_007347.4): c.1549G>A (p.Val517Ile),
which occurs at the beginning of exon 14 and is predicted
to cause a valine-to-isoleucine substitution, and
c.2401G>A (p. Glu801Lys), which occurs in exon 18 and
is predicted to cause the substitution of a lysine for the
normal glutamic acid (Figure 1B). These two variants co-
segregate with the disorder in 11 members of sub-pedigree
1E, and all of the affected individuals in this sub-pedigree
carry one chromosome with these variants, which does
not occur in any other branches of this family. The wild-
type valine and glutamic acid at these positions are highly
conserved across mammals (Figure S1) and completely
conserved in normal Cameroonian control individuals,
normal Pakistani control individuals, neurologically
normal North American control individuals, 1000 Ge-
nomes individuals, and NHLBI ESP6400 individuals, who
together represent >19,000 chromosomes.
Sequencing 96 unrelated Cameroonians who stutter
identified the same two rare AP4E1 coding variants in
two additional individuals. A survey of 12 SNP variants ex-
tending across 47 kb of AP4E1 genomic sequence contain-
ing these two variants identified a SNP haplotype shared
by these two individuals and the affected members of
Cameroonian family CAMST01. This haplotype was
observed in 1/42 (2.4%) Cameroonian chromosomes not
containing these variants. This suggests that the
c.1549G>A and c.2401G>A variants share a common
origin on a haplotype that is uncommon in the Cameroo-
nian population.
Sequencing 96 normally fluent Cameroonian control in-
dividuals identified a single missense variant (c.632G>A
[p.Arg211Gln]) in one individual. Sequencing AP4E1 in
unrelated affected individuals from Cameroon (n ¼ 93),
Pakistan (n ¼ 132), and North America (n ¼ 711) revealed
23 other rare variants in this gene, including small (1- to
3-bp) deletions, insertions, duplications, frameshifts, and718 The American Journal of Human Genetics 97, 715–725, Novembstop codons (Table 1). No germline small deletion, inser-
tion, frameshift, or stop-codon variants of AP4E1 occur
in any of our Cameroonian (n ¼ 94), Pakistani (n ¼ 96),
or North American (n ¼ 368) control individuals (total
n ¼ 558).
To gain a better idea of the rate of such loss-of-function
variants in the general population, we investigated the
1000 Genomes and NHLBI ESP (ESP6400) databases,
which represent individuals who are unphenotyped for
speech fluency. We found a total of three such variants—
one stop-gain and two splice-site variants—in individuals
of East-Asian origin (the CDX [Chinese Dai in Xishuang-
banna, China] population, consisting of 93 individuals).
Our finding of three loss-of-function variants in the
~19,000 chromosomes in these databases—which contain
individuals of similar sub-Saharan West African (the YRI
[Yoruba in Ibadan, Nigeria], GWD [Gambian in Western
Divisions in the Gambia], MSL [Mende in Sierra Leone],
and ESN [Esan in Nigeria] populations; n ¼ 405), South
Asian (the ITU [Indian Telugu from the UK], STU [Sri Lan-
kan Tamil from the UK], BEB [Bengali from Bangladesh],
PJL [Punjabi from Lahore, Pakistan], and GIH [Gujarati In-
dian from Houston, Texas] populations; n ¼ 489), and
North American ancestries as our stuttering and control in-
dividuals—suggests that germline AP4E1 loss-of-function
variants are very rare in the general population.
In addition to loss-of-function variants, rare missense
variants in AP4E1 were also observed (Tables 1 and 2).
We compared the rate of such variants in affected and con-
trol individuals within sub-populations. AP4E1 variants
were found at a higher frequency in Pakistani affected in-
dividuals (11/132) than in Pakistani control individuals
(1/96; Chi-square p ¼ 0.0149) and at a higher frequency
in Cameroonian affected individuals (9/93) than in Cam-
eroonian control individuals (1/94; Chi-square p ¼
0.0088). Variants occurred at a frequency of 2.1% (15/
711) in North American affected individuals and a fre-
quency of 1.9% (7/368) in North American control indi-
viduals (Chi-square p ¼ 0.81). Thus, AP4E1 variants were
significantly more frequent in affected individuals than
in control individuals in two of the three populations in
the study.
We sought to estimate the effects of the rare missense
variants found in affected and control individuals by using
PolyPhen-2.19 These results are shown in Tables 1 (affected
individuals) and 2 (control individuals). The mean Poly-
Phen-2 score of the missense variants found in affected in-
dividuals was 0.67, whereas the mean score of those found
in control individuals was 0.56.
A total of 30 germline rare AP4E1 variants of all types
(missense and loss of function) exist in the 1000 Genomes
phase 3 dataset, consisting of 6,508 chromosomes that
include individuals of sub-Saharan West African, South
Asian, and European populations, indicating that such var-
iants are rare worldwide. Although individuals in databases
have unknown speech-fluency phenotypes, the rate of rare
AP4E1 variants in our stuttering individuals is higher thaner 5, 2015
Table 1. Summary of Rare AP4E1 Variants in Population-Matched Stuttering Individuals
cDNA Change
Amino Acid
Change SNP ID
Stuttering Individuals and Families (n ¼ 936)a
Population-
Matched
Control
Individuals
(n ¼ 558)
No. of Individuals in
Population Databases
PolyPhen-2
Score
CAMST01
(1 Family) STCR ( n ¼ 92) PKST (60 Families)
PKSTR
(n ¼ 72)
NA þ NIH
(n ¼ 711)
1000
Genomes
NHLBI
ESP6400
c.2_118(1_3) non-coding unknown   PKST9 [3]  NA276, NA363    
c.4G>A non-coding unknown  STCR132, STCR201      2 
c.7G>A non-coding unknown     Na0672    
c.286T>G p.Phe96Val unknown   PKST27 [1]      1.000
c.542þ3A>G non-coding unknown     Na0689    
c.613C>A p.His205Asn rs148499164     NA182   5 0.924
c.833delT p.Leu278* unknown     NA272    
c.741dup p.Val248Cysfs*41 unknown     NA275    
c.932A>G p.Asn311Ser rs536656846     Na0166    0.910
c.977C>T p.Ser326Phe rs372479885     Na0507   1 0.897
c.1151A>G p.His384Arg unknown     NIH25    1.000
c.1276A>C p.Ile426Leu rs148817957     NA22 ND05461 3 11 0.924
c.1424C>T p.Ala475Val rs200678853   PKST95 [2]      1.000
c.1549G>A p.Val517Ile unknown 1E [12] STCR102, STCR199       1.000
c.1624A>G p.Met542Val unknown   PKST26 [1], PKST81 [3]  NA136    0.000
c.1851þ1_4dupGTAA non-coding unknown    PKSTR25     
c.1867T>C p.Ser623Pro unknown     NA41 ND08851 – – 1.000
c.2383delA p.Arg795Glyfs*19 unknown     NA173    
c.2401G>A p.Glu801Lys unknown 1E [12] STCR102, STCR199       0.006
c.2570C>G p.Ser857* unknown   PKST44 [2]      
c.2713T>C p.Ser905Pro unknown     NA217    0.013
c.2932C>T p.Pro978Ser rs141278078   PKST87 [2]     6 0.001
c.3238A>G p.Ile1080Val unknown   PKST69 [1]      0.000
c.3266T>G p.Leu1089Arg unknown   PKST32 [1] PKSTR59     0.990
c.3314G>A p.Arg1105Gln rs139640763 1E [1]      2 1 1.000
Abbreviations are as follows: CAMST01, Cameroonian family; STCR, Cameroonian unrelated stuttering individuals; PKST, Pakistani families with stuttering individuals; PKSTR, Pakistani unrelated stuttering individuals; NA,
unrelated North American stuttering individuals; Na, single unrelated stuttering individuals from North American families; , variant has zero allele frequency.
aBrackets indicate the number of affected individuals within the family.
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Table 2. Summary of Rare AP4E1 Variants in Population-Matched Control Individuals
cDNA
Change
Amino Acid
Change SNP ID
Population-Matched Control
Individuals (n ¼ 558)
Stuttering
Individuals
(n ¼ 936)
No. of Individuals in
Population Databases PolyPhen-2
RC
(n ¼ 94)
PKNR
(n ¼ 96)
NDPT
(n ¼ 368)
1000
Genomes
NHLBI
ESP6400 Score
c.254T>C p.Ile85Thr rs147005786   ND05681   2 0.890
c.434C>G p.Thr145Ser rs200034177   ND07655   1 0.966
c.632G>A p.Arg211Gln unknown RC25      0.507
c.791A>G p.Asn264Ser rs145541719  PKNR87   7 1 0.002
c.1276A>C p.Ile426Leu rs148817957   ND05461 NA22 3 11 0.924
c.1852G>A p.Val618Ile rs142215198   ND05770   4 0.548
c.1867T>C p.Ser623Pro unknown   ND08851 NA41   1.000
c.2117T>A p.Ile706Lys unknown   ND05125    0.211
c.2437A>G p.Met813Val unknown   ND07113    0.000
Abbreviations are as follows: RC, random Cameroonian control individuals; PKNR, random Pakistani population control individuals; NDPT, neurologically normal
control individuals; NA, unrelated North American stuttering individuals; , variant has zero allele frequency.the rate of such variants in similar populations within the
1000 Genomes phase 3 dataset. For example, we observed
a higher rate of variants in our Cameroonian affected indi-
viduals (9/93) than in the unphenotyped West African in-
dividuals (5/405; Chi-square ¼ 31.81, p ¼ 8.9 3 106) and
in Pakistani affected individuals (11/132) than in unphe-
notyped South Asians (8/489; Chi-square ¼ 15.72, p ¼
7.35 3 105). Our North American stuttering individuals
showed a trend toward a higher rate of rare AP4E1 variants
(15/711) than did ethnically similar unphenotyped
Europeans in the 1000 Genomes database (4/503; Chi-
square ¼ 3.3, p ¼ 0.069).
The variants observed in our unrelated stuttering indi-
viduals were all rare, but two were observed in unrelated
affected individuals from different populations (Table 1).
We also evaluated the hypothesis that rare variants in
genes encoding the three other subunits of the AP-4 com-
plex (AP4M1 [MIM: 602296], AP4S1 [MIM: 607243], and
AP4B1 [MIM: 607245]) are more frequent in stuttering in-
dividuals than in control individuals. We observed rare
non-synonymous coding variants in these three genes at
similar rates in affected and control individuals (Tables
S1A–S1C).
Clinical Studies
Homozygous AP4E1 deficiency (MIM: 607244) has been
described in five individuals to date,20–22 although the ef-
fects of heterozygosity for such variants have not been
carefully evaluated. We sought to determine whether our
stuttering subjects, all of whom are heterozygous for an
AP4E1 variant, display any symptoms previously associ-
ated with homozygous AP4E1 deficiency. In family
CAMST01 sub-pedigree 1E, eight members (IV-150, III-
142, III-143, III-145, III-147, III-148, III-149, and III-151
in Figure 1B), all of whom carry the AP4E1 c.1549G>A
and c.2401G>A variants, underwent clinical examinations720 The American Journal of Human Genetics 97, 715–725, Novembat the NIH Clinical Center. Particular attention was paid to
potential symptoms previously observed in the five indi-
viduals carrying homozygous loss-of-function mutations
in AP4E1.20–22 These symptoms included intellectual
disability and pseudobulbar symptoms such as drooling,
stereotypic laughter, and oral motor spasticity. These indi-
viduals also demonstrated spasticity and hyperreflexia in
the extremities, microcephaly, severe ambulation prob-
lems, seizures, incontinence, conductive hearing loss, se-
vere speech impairments, and mycobacterial disease.
Given these findings, our evaluation procedures
included examination of general cognitive function,
speech, and language, a comprehensive neurological eval-
uation including H-reflex and limb-dexterity tests, audio-
logical evaluation, and electroencephalography (EEG). In
addition, individuals also underwent electromyography
(EMG) and nerve conduction velocity (NCV) tests, electro-
cardiography, MRI, X-rays of long bones, complete blood
count (CBC), and a comprehensive blood-chemistry panel,
as well as assessment of general medical history and phys-
ical examination.
No consistent notable clinical findings were observed in
our eight subjects. There was no evidence of develop-
mental delay or mycobacterial disease. Cognitive and lan-
guage assessments revealed no evidence of general intellec-
tual or cognitive dysfunction or of deficits in speech and
language comprehension or production other than stutter-
ing. Head circumference was within normal limits in all
subjects. Neurological evaluation revealed no evidence of
cranial-nerve abnormalities or pseudobulbar symptoms.
Motor examination was normal in that no weakness or hy-
pertonia was noted. Sensory examination was normal.
Deep tendon reflexes were normal, pathological reflexes
were absent, and cerebellar exam was intact. H-reflexes
andmanual dexterity were normal in the subset of individ-
uals tested. Audiometry and auditory brainstem responseser 5, 2015
Figure 2. Assembly of AP-4 Complexes
by Variant ε Subunits
(A) Schematic representation of the AP-4 ε
subunit. Single amino acid substitutions
are indicated in blue, whereas truncating
variants are depicted in red. The
numbering corresponds to the human AP-
4 ε isoform, comprising 1,137 residues
(GenBank: NP_031373.2); assignment of
domains is as in Boehm and Bonifacino.26
(B) Expression of wild-type (WT) and
variant human AP-4 ε constructs tagged at
their N termini with TSF-tagged ε con-
structs in HEK293T cells. Transfected cell
lysates were subjected to SDS-PAGE fol-
lowed by immunoblotting with anti-
FLAG antibody.
(C) Assembly ofWTand variant TSF-tagged
ε constructs into AP-4 complexes. Lysates
of transfected HEK293T cells were incu-
bated with StrepTactin Sepharose beads.
Pulled-down complexes were subsequently
eluted with d-desthiobiotin and subjected
to SDS-PAGE and immunoblotting with
anti-AP-4 b4 antiserum.16
(D) Immunoblot membranes with samples
of the StrepTactin pull-down assays shown
in (C) were stripped and subjected to addi-
tional immunoblotting with anti-FLAG
antibody.
(E) The assembly of AP-4 complexes byWT
and variant ε constructs (pulled-down
complexes detected by anti-b4; blots in C)
was calculated in relation to the total
expression of the cognate ε constructs in
transfected HEK293T cells (blots in B).
Blots were subjected to densitometric anal-
ysis with Image J software. Results are ex-
pressed as the percentage of assembly
measured for WT ε (percentage of WT ε).were normal, except for in one individual (age 63 years)
who showed hearing changes consistent with age-related
hearing loss. EEG showed no evidence of epileptiform ac-
tivity. EMG and NCV tests were normal. X-rays revealed
no evidence of long-bone deformities. CBC and blood
chemistries were essentially within normal limits.
The heterozygous carrier parents of the severely affected
AP4E1-deficient individuals have been previously reported
to be medically normal. Our stuttering subjects with rare
variants in AP4E1 are all heterozygotes carrying a single
copy of the variants, consistent with a lack of the severe
symptoms reported in homozygotes.
Biochemical Effects of AP4E1 Variants Found in
Stuttering
AP4E1 encodes the ε subunit of AP-4, a heterotetrameric
(ε-b4-m4-s4) complex involved in the sorting of trans-The American Journal of Human Genmembrane proteins at the trans-Golgi
network (TGN).16,23–25 The rare vari-
ants identified in the stuttering sub-
jects mapped to all three domains of
the ε subunit: trunk, hinge, and ear(Figure 2A). To better understand the effects of these vari-
ants, we constructed vectors that express wild-type and
variant AP-4 ε proteins tagged at the N terminus with TSF
epitopes. Immunoblot analysis of HEK293T cells trans-
fected with an antibody to the FLAG epitope showed
that all the variant genes were expressed and that their pro-
tein products had the predicted apparent molecular masses
(Figure 2B). The truncating variants c.741dup (p.Val248-
Cysfs*41), c.833delT (p.Leu278*), c.2383delA (p.Arg795-
Glyfs*19), and c.2570C>G (p.Ser857*) produced ε proteins
of reduced apparent molecular mass, as expected
(Figure 2B). The effects of AP4E1 variants on the assembly
of the AP4 complex were measured with a well-character-
ized antibody to the b4 subunit of this complex. Trans-
genic-protein pull-down using StrepTactin beads and
subsequent immunoblotting for the endogenous b4 sub-
unit of AP-4 showed reduced co-isolation of b4 with theetics 97, 715–725, November 5, 2015 721
Figure 3. The NAGPA Cytosolic Tail Interacts with m Subunits of
AP Complexes
(A) Amino acid sequence of the human NAGPA cytosolic tail
shows a YXXØmotif characteristic of endocytic and lysosome-tar-
geting signals (X is any amino acid, and Ø is a bulky hydrophobic
residue). Numbering corresponds to the isoform comprising 515
residues (UniProt: Q9UK23).
(B) Y2H analysis showed that the NAGPA cytosolic tail interacts
with the m subunits of AP-1 (both the m1A and m1B isoforms),
AP-2, and AP-4. Interactions depend on residues Tyr488 and
Leu491 in the YXXØ-based sequence of the NAGPA tail and on
the Tyr486 residue located immediately upstream. The NAGPA
cytosolic tail was subcloned in a Y2H Gal4 BD vector, whereas
the AP m subunits were subcloned in a Gal4 AD vector. Growth
on the His plates is indicative of interactions, whereas growth
on theþHis plate is a control for viability and loading of all double
transformants. Co-transformation of the BD-NAGPA tail con-
structs with AD-SV40 T-Ag and of AD-m subunits with the
BD-p53 construct provided negative controls for the assay. Co-
transformation of BD-p53 with AD-SV40 T-Ag provided a positive
control for interactions. Plating onHis plates containing 0.5mM
3-amino-1,2,4 triazole (3AT) provided an assay with increased
stringency conditions (3AT is a competitive inhibitor of HIS3).products of the p.Val248Cysfs*41 and p.Leu278* trun-
cating variants and the p.Ala475Val missense variant in
AP4E1 (Figures 2C–2E), indicating that these rare coding
variants reduce the assembly of the AP-4 complex. Other
variants had no appreciable effect on AP-4 assembly (Fig-
ures 2C–2E), althoughmany are predicted to be deleterious
by PolyPhen-2, and the mean effect prediction score was
slightly higher for missense variants found in our stutter-
ing individuals (0.67) than for missense variants in our
matched control individuals (0.56) (Tables 1 and 2). We
also tested the effects of the rare AP4E1 missense variants
found in our control populations. None displayed a consis-
tent effect on the assembly of the AP-4 complex within the
limits of this assay (Figure S2).
Other stuttering individuals were previously found to
have mutations in NAGPA,10 encoding the enzyme
NAGPA, which is involved in the synthesis of the mannose
6-phosphate signal for sorting of acid hydrolases to lyso-722 The American Journal of Human Genetics 97, 715–725, Novembsomes.10 Interestingly, this enzyme localizes at least in
part to the TGN,27 where AP-4 is also located.16,23 More-
over, the cytosolic tail of NAGPA contains the sequence
YAYHPLQE, which includes a tyrosine-based signal
(YHPL) fitting the YxxØ (X is any amino acid, and Ø is a
bulky hydrophobic residue) consensus motif for binding
to the m subunits of AP complexes, including AP-4.23,24,28
Residues in the YAYHPLQE sequence have been shown to
mediate sorting at different compartments, including the
TGN, endosomes, and plasma membrane.29 We used a
Y2H system to test for interaction between the NAGPA
cytosolic tail (amino acids 475–515) and the m subunits
from the AP-1, AP-2, AP-3, and AP-4 complexes. We tested
both the wild-type cytosolic tail of NAGPA and three vari-
ants (p.Tyr486Ala, p.Tyr488Ala, and p.Leu491Ala), each
containing single amino acid substitutions within the
YAYHPLQE sequence (Figure 3A). Interactions were
observed between the NAGPA tail and the m4 subunit of
AP-4, as well as the m1 and m2 subunits of AP-1 and AP-2,
respectively (Figure 3B). In contrast, no interactions be-
tween the NAGPA tail and the m3 subunits of AP-3A and
AP-3B were observed. Importantly, the interaction with
m4 was abolished when alanine substitutions were intro-
duced in the Tyr486, Tyr488, and Leu491 residues,
believed to be essential components of the YAYHPLQE
recognition motif. These observations thus demonstrate
a physical interaction between the NAGPA cytosolic tail
and the m4 subunit of AP-4.Discussion
Genetic contributions to stuttering have long been docu-
mented, and recent progress has been made in the identi-
fication of the specific genes that underlie this disorder.
Previously, we identified rare GNPTAB, GNPTG, and
NAGPA coding variants that together could account for
8%–16% of cases of persistent developmental stutter-
ing.11 These genes encode the components of the pathway
that generates the mannose 6-phosphate signal that
targets a diverse group of hydrolytic enzymes to their ulti-
mate location in the lysosome. Rare NAGPA coding vari-
ants found in stuttering subjects have been shown to
impair the biochemical function of the enzyme encoded
by this gene.30 However, it is not yet clear how such deficits
in lysosomal enzyme targeting give rise to non-syndromic
persistent stuttering, and identification of additional genes
that contribute to this disorder could aid in the under-
standing of the pathophysiology involved. Our results
now implicate rare coding variants in AP4E1, encoding
the ε subunit of AP-4, in the genesis of additional cases
of stuttering.
A number of variants, including loss-of-function vari-
ants in AP4E1, have been described in dbSNP. However,
these variants were identified in tumors rather than in
constitutional DNA and are not germline variants, such
as those we have identified in stuttering individuals. Weer 5, 2015
estimate that rare variants in AP4E1 underlie 2.1%–3.7% of
unrelated cases of persistent stuttering. The higher end of
this range is the rate at which we found rare variants in
our combined stuttering individuals. The lower range of
this estimate is the rate in our combined affected individ-
uals (35/936 [3.7%]) minus the rate of such variants in
combined population-matched control individuals (9/
558 [1.6%]). These estimates are subject to several possible
sources of error, including the unknown penetrance of
these variants in stuttering (given that less-than-complete
penetrance would reduce their contribution to the disor-
der) and potential differential contributions to the disorder
from the different populations that make up our study.
In the three other genes that encode components of the
AP4 complex (AP4B1, AP4M1, and AP4S1), we found
similar rates of rare non-synonymous coding variants in
affected and control individuals. This indicates that the
population sample and the analytic methods we used do
not show a higher rate of rare variants in stuttering individ-
uals in these genes, all of which reside at loci with no
evidence of linkage to stuttering.7–9,31,32 In addition, our
dideoxy sequencing of GANC, GATM, and GALK2, which
all lie within the sub-pedigree 1E linkage interval in chro-
mosomal region 15q, revealed no difference in the rate of
rare variants in affected and matched control individuals.
Together, these results support the view that rare variants
in other genes, either functionally related or positionally
close to AP4E1, do not show an association with stuttering.
Adaptor protein complexes are ubiquitous eukaryotic
cell components that control trafficking in the endomem-
brane system. Our results support a direct interaction be-
tween the AP-4 complex and NAGPA, which are known
to reside at the TGN. Thus, our findings of rare variants
inAP4E1not only account for additional cases of persistent
stuttering but also establish a direct link between this gene
and the products of the previously identified stuttering-
associated genes. Although our knowledge of the full spec-
trum of genetic causes of stuttering remains incomplete,
our results to date suggest that deficits in intracellular
trafficking, particularly that of the endosomal transport
system, contribute to persistent developmental stuttering.
This intracellular trafficking system is ubiquitous in
most eukaryotic cells, so it is not surprising that homozy-
gous mutations in AP4E1 (along with mutations in
GNPTAB and GNPTG) lead to rare syndromes with severe
effects in many different organs and tissues.20–22,33
Because our stuttering individuals all carry only a single
copy of a rare coding variant in AP4E1, they were not ex-
pected to display any of the symptoms previously observed
in rare individuals carrying homozygous loss-of-function
mutations in this gene. Our clinical evaluations identified
a scattering of abnormal findings in this group of eight
Cameroonian subjects. However, no spastic paraplegia,
developmental disability, microcephaly, foot abnormal-
ities, short stature, or mycobacterial disease was identified
in these subjects. Although deficits in speech have been re-
ported in AP4E1-deficient homozygotes, stuttering per seThe Americanhas not. These homozygous individuals have multiple
developmental disabilities, and their speech deficits might
be secondary to their general neurologic deficits. Our sub-
jects did not display speech deficits other than stuttering.
Thus, we could find no evidence supporting the view
that non-syndromic persistent developmental stuttering
is a mild presentation of the syndrome seen in homozy-
gous AP4E1 deficiency.
Our current results establish a possible link between the
AP-4 complex and the product of NAGPA, which has previ-
ously been associated with stuttering.10,11 These proteins
participate in the control of endosomal and/or lysosomal
trafficking. Defects in this process are an increasingly
recognized cause of neurologic disorders, ranging from
rare Mendelian disorders such as Charcot-Marie-Tooth
disease type 1C (MIM: 601098), Niemann-Pick disease
type C (MIM: 257220), and Perry syndrome (MIM:
168605)34–36 to more common genetically complex disor-
ders such as Alzheimer and Parkinson diseases.37 Further
studies are needed to address the question of how AP-4 def-
icits could lead to a specific deficit in speech and to better
elucidate the contribution of such deficits to the total
number of stuttering cases. However, our results suggest a
cellularmechanism for the neuronal pathology underlying
stuttering and place this poorly understood disorder in the
mainstream of neurological disease.Accession Numbers
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